Department of Neurology, St. Josef Hospital, Ruhr-University Bochum, Gudrunstr. 56, 44791, Bochum, Germany.
J Neuroinflammation. 2019 Mar 9;16(1):58. doi: 10.1186/s12974-019-1445-0.
Corticosteroids dominate in the treatment of chronic autoimmune neuropathies although long-term use is characterized by devastating side effects.
We introduce the intrathecal application of the synthetic steroid triamcinolone (TRIAM) as a novel therapeutic option in experimental autoimmune neuritis in Lewis rats RESULTS: After immunization with neuritogenic P2 peptide, we show a dose-dependent therapeutic effect of one intrathecal injection of 0.3 or 0.6 mg/kg TRIAM on clinical and electrophysiological parameters of neuritis with a lower degree of inflammatory infiltrates (T cells and macrophages) and demyelination in the sciatic nerve. In vitro studies in Schwann cell cultures showed an increased expression of IL-1 receptor antagonist and reduced expression of Toll-like receptor 4 after incubation with TRIAM as well as a protective effect of TRIAM against oxidative stress after HO exposure.
Intrathecal TRIAM application could be a novel immunomodulatory and potentially neuroprotective option for autoimmune neuropathies with a direct effect on Schwann cells.
尽管长期使用皮质类固醇会产生破坏性的副作用，但它们在治疗慢性自身免疫性神经病中占主导地位。
我们介绍了鞘内应用合成类固醇曲安奈德（TRIAM）作为实验性自身免疫性神经炎中Lewis 大鼠的一种新的治疗选择。
在用致神经炎 P2 肽免疫后，我们发现鞘内注射 0.3 或 0.6mg/kg TRIAM 对神经炎的临床和电生理参数具有剂量依赖性的治疗作用，坐骨神经中的炎症浸润（T 细胞和巨噬细胞）和脱髓鞘程度较低。在雪旺细胞培养物中的体外研究表明，TRIAM 孵育后白细胞介素 1 受体拮抗剂表达增加，Toll 样受体 4 表达减少，HO 暴露后 TRIAM 具有保护作用。
鞘内 TRIAM 应用可能是一种新型的免疫调节和潜在的神经保护选择，对自身免疫性神经病具有直接作用 Schwann 细胞。
